Associations of endogenous estrogens, plasma Alzheimer’s disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women

Background Women carrying the APOE4 allele are at greater risk of developing Alzheimer’s disease (AD) from ages 65–75 years compared to men. To better understand the elevated risk conferred by APOE4 carrier status among midlife women, we investigated the separate and interactive associations of endogenous estrogens, plasma AD biomarkers, and APOE4 carrier status on regional brain volumes in a sample of late midlife postmenopausal women. Methods Participants were enrolled in MsBrain, a cohort study of postmenopausal women (n = 171, mean age = 59.4 years, mean MoCA score = 26.9; race = 83.2% white, APOE4 carriers = 40). Serum estrone (E1) and estradiol (E2) levels were assessed using liquid chromatography–tandem mass spectrometry. APOE genotype was determined using TaqMan SNP genotyping assays. Plasma AD biomarkers were measured using single molecule array technology. Cortical volume was measured and segmented by FreeSurfer software using individual T1w MPRAGE images. Multiple linear regression models were conducted to determine whether separate and interactive associations between endogenous estrogen levels, plasma AD biomarkers (Aβ42/Aβ40, Aβ42/p-tau181), and APOE4 carrier status predict regional brain volume (21 regions per hemisphere, selected a priori); and, whether significant interactive associations between estrogens and AD biomarkers on brain volume differed by APOE4 carrier status. Results There was no main effect of APOE4 carrier status on regional brain volumes, endogenous estrogen levels, or plasma AD biomarkers. Estrogens did not associate with regional brain volumes, except for positive associations with left caudal middle frontal gyrus and fusiform volumes. The interactive association of estrogens and APOE4 carrier status on brain volume was not significant for any region. The interactive association of estrogens and plasma AD biomarkers predicted brain volume of several regions. Higher E1 and E2 were more strongly associated with greater regional brain volumes among women with a poorer AD biomarker profile (lower Aβ42/40, lower Aβ42/p-tau181 ratios). In APOE4-stratified analyses, these interactions were driven by non-APOE4 carriers. Conclusion We demonstrate that the brain volumes of postmenopausal women with poorer AD biomarker profiles benefit most from higher endogenous estrogen levels. These findings are driven by non-APOE4 carriers, suggesting that APOE4 carriers may be insensitive to the favorable effects of estrogens on brain volume in the postmenopause.

Background: Women carrying the APOE4 allele are at greater risk of developing Alzheimer's disease (AD) from ages 65-75 years compared to men.To better understand the elevated risk conferred by APOE4 carrier status among midlife women, we investigated the separate and interactive associations of endogenous estrogens, plasma AD biomarkers, and APOE4 carrier status on regional brain volumes in a sample of late midlife postmenopausal women.
Methods: Participants were enrolled in MsBrain, a cohort study of postmenopausal women (n = 171, mean age = 59.4 years, mean MoCA score = 26.9;race = 83.2%white, APOE4 carriers = 40).Serum estrone (E1) and estradiol (E2) levels were assessed using liquid chromatography-tandem mass spectrometry.APOE genotype was determined using TaqMan SNP genotyping assays.Plasma AD biomarkers were measured using single molecule array technology.Cortical volume was measured and segmented by FreeSurfer software using individual T1w MPRAGE images.Multiple linear regression models were conducted to determine whether separate and interactive associations between endogenous estrogen levels, plasma AD biomarkers (Aβ42/Aβ40, Aβ42/p-tau181), and APOE4 carrier status predict regional brain volume (21 regions per hemisphere, selected a priori); and, whether significant interactive associations between estrogens and AD biomarkers on brain volume differed by APOE4 carrier status.
Results: There was no main effect of APOE4 carrier status on regional brain volumes, endogenous estrogen levels, or plasma AD biomarkers.Estrogens did not associate with regional brain volumes, except for positive associations with left caudal middle frontal gyrus and fusiform volumes.The interactive association of estrogens and APOE4 carrier status on brain volume was not significant for any region.The interactive association of estrogens and plasma AD biomarkers

Introduction
Women comprise two-thirds of individuals living with Alzheimer's disease (AD) in America (Alzheimer's Association, 2023).In women, APOE4 genotype is a stronger risk factor for developing AD from ages 65 to 75 years compared to men and confers disproportionate adverse effects on AD biomarkers at each disease stage (Neu et al., 2017;Sundermann et al., 2018).In studies of adults aged 70 years or older, APOE4-related adverse effects on default mode network connectivity, total tau levels, brain metabolism, and cortical volume were more pronounced in women than men (Damoiseaux et al., 2012;Sampedro et al., 2015).Women carrying the APOE4 allele also had greater spread of neurofibrillary tangles and higher amyloid deposition at ages 60-75 compared to men, as identified postmortem (Corder et al., 2004).In contrast, some findings among older APOE4 carriers demonstrate worse brain outcomes for men (Sundermann et al., 2018).Less wellknown are the factors impacting brain health for APOE4+ women at midlife, when preventative efforts are most effective.
The greater vulnerability to APOE4 effects in women has been attributed in part to the direct and interactive effects of estrogens on the brain (Valencia-Olvera et al., 2023).In animal models, estradiol (E2) influences the severity of AD biomarkers by preventing amyloid accumulation (Xu et al., 1998;Nilsen et al., 2006;Amtul et al., 2010;Kim et al., 2022) and tau hyperphosphorylation (Alvarez-De-La-Rosa et al., 2005).Furthermore, the effects of E2 on amyloid and tau have been shown to vary with APOE4 carrier status in rodent and human studies (Kunzler et al., 2014;Kantarci et al., 2016a;Depypere et al., 2023).Administration of E2 increased amyloid deposition in the hippocampus and cortex in APOE4 carrier mice only, indicating a vulnerability to E2 with the APOE4 genotype (Kunzler et al., 2014).Subsequent research showed that APOE 3/3 and 3/4 mice had enhanced spatial memory and increased CA1 apical spine density after E2 administration, but these effects were not observed in APOE 4/4 mice indicating that APOE4 homozygosity may impede the potential benefits of estrogens on the brain (Taxier et al., 2022).Human studies suggest that E2 may be either neutral or beneficial for APOE4+ women.In a large (n = 693) randomized clinical trial of menopausal hormone therapy (MHT) in early and late postmenopausal women, MHT had neutral effects on cognition regardless of APOE4 genotype (Gleason et al., 2014).However, in a subset of women (n = 68) from that trial, MHT lowered Aβ deposition compared to placebo only in APOE4+ women (Kantarci et al., 2016a).Additionally, in an observational study examining 6-month change in plasma AD biomarkers in women before and after treatment with MHT (n = 193) in comparison to non-treated controls (n = 31), there were no overall differences in biomarkers between control and MHT groups, but group differences emerged when considering APOE4 genotype (Depypere et al., 2023).Specifically, APOE4+ women who did not take MHT had worse AD biomarker outcomes (i.e., greater reduction in Aβ-42/p-tau 231 ratio) over time than women who took MHT.Further, among those in the MHT group, Aβ1-42 concentrations were higher (better) in APOE4+ women compared to APOE4− women.Thus, there is some consistency from basic and clinical science studies that APOE ε4 genotype might modify the effect of supplemental exogenous E2 on AD biomarkers, with greater benefits observed among APOE4+ women.It is yet unknown whether the effect of endogenous estrogens on the brain varies with APOE genotype.
In the postmenopause, women have low levels of endogenous E2 and estrone (E1) due to the cessation of ovarian steroid production (Randolph et al., 2011;Kim et al., 2017).While E2 levels are low overall, there are individual differences in trajectories of change of endogenous E2 across the menopause transition and into the postmenopause (Tepper et al., 2012).Trajectories include slow decline, flat slope, rise/slow decline, and rise/steep decline, associating differentially with biological and sociodemographic factors such as obesity, race, and ethnicity.Furthermore, endogenous E2 levels in the postmenopause have been associated with neuroimaging measures, such as resting state functional connectivity, particularly parahippocampal functional connectivity (Testo et al., 2024).
To better understand whether APOE4+ women are differentially sensitive to estrogen loss in the postmenopause, we investigated the separate and interactive associations of estrogens, plasma AD biomarkers, and APOE4 carrier status on regional brain volumes in a sample of late midlife postmenopausal women.We were particularly interested in whether the interactive effects of endogenous estrogens and plasma AD biomarkers on brain volume vary by APOE4 carrier status.

DK Atlas Region Estrogen reference
Frontal lobe ER-alpha and ER-beta distribution in postmortem human brain (Österlund et al., 2000;Osterlund and Hurd, 2001) Reviews of estrogen signaling during the menopause transition (Brinton et al., 2015), in cholinergic (Newhouse and Dumas, 2015), glutamatergic, GABAergic, dopaminergic, and serotonergic pathways (Barth et al., 2015) Superior frontal ERs in AD patients postmortem (Kelly et al., 2008) Rostral middle frontal gyrus ER-alpha and ER-beta distribution in postmortem human brain (Österlund et al., 2000;Osterlund and Hurd, 2001) ER-alpha is downregulated in the hippocampus in postmortem women with AD (Hu et al., 2003;Ishunina et al., 2007), but upregulated across the menopause transition (Ishunina et al., 2007) Reviews of estrogen signaling during the menopause transition (Brinton et al., 2015), in cholinergic (Newhouse and Dumas, 2015), glutamatergic, GABA-ergic, dopaminergic, and serotonergic pathways (Barth et al., 2015) Entorhinal cortex Thinner in women who underwent bilateral salpingo-oophorectomy (Zeydan et al., 2019) Parahippocampal gyrus Positive association between E2 and volume across menstrual cycle (Zsido et al., 2023) Thinner in women who underwent bilateral salpingo-oophorectomy (Zeydan et al   United States (Thurston et al., 2023).The MsBrain cohort (N = 274) is recruited from two sources: 170 participants previously (2015-2018) partook in MsHeart, a cross-sectional study of menopausal vasomotor symptoms (VMS) and cardiovascular health (Thurston et al., 2016), and 104 participants were recruited from the wider Pittsburgh community.Exclusion criteria in MsHeart included: current smoking; reported history of cardiovascular disease/stroke/ cerebrovascular accident; insulin-dependent diabetes; Parkinson's disease; hysterectomy and/or bilateral oophorectomy; current pregnancy; and use of HT (oral or transdermal estrogen and/or progesterone), select cardiovascular medications (beta blockers, calcium channel blockers, alpha-2 adrenergic agonists), selective estrogen receptor modulators (SERMS), aromatase inhibitors (AI), selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).MsBrain exclusion criteria additionally included: a reported history of dementia; seizure disorder; brain tumor; Parkinson's disease; a history of head trauma with loss of consciousness; contraindications to MRI (e.g., metal in the body); current chemotherapy; active substance use; and pregnancy.In total, 238 women completed neuroimaging.Of those women, 21 were excluded due to incidental findings, seven learned English as a second language, four were missing hormone data, and three were perimenopausal.Given the neuroprotective effects of the APOE2 allele (see Li et al., 2020), an additional 32 women who possessed the APOE2 allele were excluded, yielding a final sample of 171 women.

Design
At the first visit, demographic and medical history were obtained.Body mass index (BMI) was calculated (kg/m 2 ) from weight and height measured using a digital scale and a fixed stadiometer.Menopause status was determined using STRAW+10 criteria (Harlow et al., 2012).Three days after visit one, participants returned for a second visit wherein they underwent a blood draw and completed a one-hour cognitive test battery.During the cognitive testing, participants completed the Montreal Cognitive Assessment (MoCA) which is a brief screening instrument designed to identify mild cognitive impairment (Nasreddine et al., 2005).A MoCA score below 26 of 30 possible points indicates possible mild cognitive impairment (Nasreddine et al., 2005).At a third visit, on average 12 days after visit one, participants completed a neuroimaging protocol.Study procedures were approved by the University of Pittsburgh Human Research Protection Office.All participants provided written informed consent.

Phlebotomy
Phlebotomy was performed after an eight-hour overnight fast.Blood was processed onsite with a Fisher Scientific Sorvall ST16R centrifuge and frozen in a − 80°C freezer until transportation to labs for assays.

Estrogen
Serum E1 and E2 were assessed via liquid chromatographytandem mass spectrometry at the University of Pittsburgh's Small Biomarker Core, with inter-and intra-assay coefficients of variation of 5.0 and 8.1%, respectively.The lower limit of detection was 1.0 pg/mL for both estrogens.This method is sensitive to endogenous estrogen levels in the postmenopause (Nelson et al., 2004).

Blood-based AD biomarkers
Plasma biomarker concentrations of Aβ42, Aβ40, and p-tau 181 were measured using Single molecule array (SIMOA) technology on an HD-X instrument (Quanterix).Frozen samples underwent a single thawing cycle.Plasma Aβ42 and Aβ40 were measured using the Neurology 4-Plex E (#103670) and p-tau181 was measured with the p-tau181 V2 Advantage (#103714) commercial assays from Quanterix.For each assay, quality control samples of different concentrations were analyzed in duplicates to estimate reproducibility.The pooled quality control data showed that the within-and between-run Regions of interest identified in estradiol and AD biomarker analyses.

Neuroimaging
All participants underwent neuroimaging at the MR Research Center of the University of Pittsburgh on a 3 T Siemens Tim Trio MR scanner, with a Siemens 64-channel head coil.Brain imaging assessments were performed MR pulse sequences were optimized for the multichannel coil and follow the Human Connectome Project protocol.Structural data was acquired using a T1-weighted 3D Magnetizationprepared rapid gradient echo (MPRAGE: TR/TI/FA = 2300/900/9°, voxel size = 1 mm × 1 mm × 1 mm, Grappa 2).Regional brain volumes were divided by estimated total intracranial volume.

Analyses 2.3.1 A priori regional brain volumes
There are 68 individual regions of interest (ROIs) included in the DK atlas.We refined the atlas to focus on 21 ROIs in regions with a high density of estrogen receptors and/or estrogen signaling, as determined by previous literature (see Table 1).We selected 13 frontal ROIs and 8 temporal ROIs in each hemisphere for a total of 42 ROIs.

Data analysis plan
Independent-samples t-tests and chi-square analyses were conducted to examine demographic differences between APOE4 carriers and non-carriers.After preliminary data visualization, E2, E1, and p-tau 181 were log-transformed prior to analyses.Multiple linear regressions were used to examine the separate and interactive effects of estrogens (i.e., E2 and E1), AD biomarkers (i.e., Aβ42/40 and Aβ42/p-tau 181), and APOE4 carrier status on regional brain volumes controlling for age, years of education, race, and BMI.All statistical analyses were conducted using R Statistical Software (Version 4.3.1;R Core Team, 2023).Interactive effects of estradiol and AD biomarker ratios on regional brain volumes.AD biomarker ratios are divided into quintiles.B, regression coefficient estimate for the interaction term; p, p value for the interaction term.10.3389/fnagi.2024.1426070 Frontiers in Aging 08 frontiersin.org

Full sample analyses
We first conducted multiple linear regressions to evaluate the independent associations of E1, E2, and APOE4 with ROIs.We next conducted multiple linear regressions to evaluate the interactions between: estrogens and APOE4 status; estrogens and Aβ-42/40 ratio; and estrogens and Aβ-42/p-tau 181 ratio.We controlled for age, years of education, race, and BMI in all analyses.

APOE4 stratified analyses
To determine whether any significant interactive associations of estrogens and AD biomarkers with brain volumes varied by APOE4 carrier status, we conducted follow-up linear regressions stratifying by APOE4 carrier status.Specifically, for each ROI volume that was predicted by the interaction of estrogens and AD biomarkers in the full sample, we conducted the same linear regressions as delineated above in the APOE4+ and APOE4− groups separately again controlling for age, years of education, race, and BMI.
Multiple linear regressions investigating the interaction of E2 and Aβ-42/40 on regional brain volumes revealed that the association between E2 and the volumes of the right frontal pole (p = 0.04), left lateral orbitofrontal gyrus (p = 0.04), left pars orbitalis (p = 0.01), left pars triangularis (p = 0.04), left rostral middle frontal gyrus (p = 0.04), and left transverse temporal gyrus (p < 0.01) depend on the Aβ-42/40 ratio (Table 4; Figure 1).In addition, regression analyses showed an interactive association of E2 and Aβ-42/p-tau 181 ratio with volumes of the right caudal anterior cingulate gyrus (p = <0.01)and the left caudal middle frontal gyrus (p = 0.04; Table 4; Figure 1).The pattern of results was similar in all regions, such that the association between E2 levels and brain volume was stronger and more positive for women with lower Aβ42/40 or Aβ42/p-tau 181 ratios, compared to women with higher AD biomarker ratios (Figure 2).

APOE4 stratified
For each ROI where an interaction of E2 and AD biomarkers was observed, we conducted the same regression analyses stratified by APOE4 and non-APOE4 carriers.There was an interactive association of E2 and Aβ-42/40 ratio on the volumes of the right frontal pole (p = 0.04), left lateral orbitofrontal gyrus (p = 0.03), left pars orbitalis (p < 0.01), and left transverse temporal gyrus (p < 0.001) among the non-APOE4 carrier group only (Table 5).Additionally, there was an interaction of E2 and Aβ-42/p-tau 181 ratio on volumes of the right Regions of interest identified in estrone and AD biomarker analyses.5).When comparing women with lower (more severe) AD biomarker ratios, APOE4− women showed a stronger positive relationship between E2 and brain volumes in all ROIs compared to APOE4+ women (Figures 5, 6).Among women with higher (normal) AD biomarker ratios, non-APOE4 carriers show a weak negative relationship between E2 and brain volumes in all significant ROIs.In APOE4 carriers, the pattern of results differs by brain region, yet there were no interactions of E2 and AD biomarkers on brain volume and thus the biomarker slopes are not significantly different from each other (Figures 5, 6).Among the ROIs associated with the interaction of E1 and AD biomarkers above, we conducted the same regression analyses stratified by APOE4 carrier status.Of those ROIs, there was an interaction of E1 and Aβ-42/40 ratio on the volumes of the left lateral orbitofrontal gyrus (p = 0.04), left pars orbitalis (p = 0.04), and left transverse temporal gyrus (p < 0.001) among non-APOE4 carriers only (Table 5).There was also an interaction of E1 and Aβ-42/p-tau 181 ratio on volumes of the right caudal anterior cingulate gyrus (p < 0.01) and left caudal middle frontal gyrus (p = 0.03) among non-APOE4 carriers only (Table 5).When comparing women with lower (more severe) AD biomarker ratios by APOE4 groups, APOE4− women have a stronger positive relationship between E1 and brain volumes compared to APOE4+ women (Figures 7, 8).Among women with higher (normal) AD biomarker ratios, APOE− women showed a weak negative relationship between E1 and brain volumes in all ROIs.There were no significant interactions of E1 and either AD biomarker on brain volume among APOE4 carriers (Figures 7, 8).

Discussion
In a sample of late midlife, postmenopausal women, we investigated the interactive associations of endogenous estrogens and plasma AD biomarkers with volumes in brain areas rich in estrogen receptors.We had a particular interest in whether these associations differed by APOE4 carrier status.Independently, Interactive effects of estrone and AD biomarker ratios on regional brain volumes.AD biomarker ratios are divided into quintiles.B, regression coefficient estimate for the interaction term; p, p value for the interaction term.10. 3389/fnagi.2024.1426070Frontiers in Aging Neuroscience 10 frontiersin.orgendogenous estrogens APOE4 carrier status were not significantly associated with brain nor were there interactions between estrogen levels and APOE4 carrier status in relation to regional brain volumes.However, there were interactions between estrogens and plasma AD biomarkers on volume of several brain regions; both E1 and E2 had a stronger positive association with regional brain volumes among women with worse AD biomarkers as measured by lower Aβ42/40 or Aβ42/p-tau 181 ratios.Furthermore, APOE4-stratified analyses revealed that these interactions were primarily driven by non-APOE4 carriers.Among APOE4 carriers, endogenous estrogens do not associate with the volume of these brain regions regardless of the severity of AD biomarkers.Overall, these findings suggest that both endogenous E1 and E2 may positively influence brain volume in late reproductive women with higher risk of AD as evidenced by AD biomarkers but not as evidenced by APOE4 carrier status.
In analyses focusing on estrogens and APOE4 carrier status, we found no evidence that the effect of endogenous estrogens on brain volume varied with APOE4 status.The effects of estrogens on women's brain structure in the postmenopause have primarily been evaluated in randomized controlled trials of MHT, which produces higher levels of estrogen (Resnick et al., 2009;Kantarci et al., 2016bKantarci et al., , 2018)).The findings across those studies are inconsistent.The Women's Health Initiative Memory Study (WHIMS) found that women randomized to receive conjugated equine estrogens (CEE) had smaller frontal lobe volumes and slightly lower hippocampal volumes compared to women on placebo (Resnick et al., 2009).In the Kronos Early Estrogen Prevention Study (KEEPS), a randomized trial of MHT in early postmenopausal women, there was no effect of MHT on whole brain volumes after two years of use of transdermal E2 or CEE, but women on CEE had higher rates of ventricular expansion compared to placebo (Kantarci et al., 2016b).After three years of MHT use in the KEEPS, women randomized to receive transdermal E2 showed lower longitudinal decreases in dorsolateral prefrontal cortex (dlPFC) volume compared to placebo (Kantarci et al., 2018).E2 treatment also increased dlPFC volume in non-human primates (Hao et al., 2006) and enhanced functional connectivity between the dlPFC and hippocampus in postmenopausal women (Ottowitz et al., 2008).In the observational study of women in the European Prevention of Alzheimer's Disease (EPAD) cohort, MHT was associated with larger entorhinal and amygdala volume in APOE4 carriers (Saleh et al., 2023).APOE4 carriers in EPAD also had larger hippocampal volumes with earlier age at MHT initiation (Saleh et al., 2023).This is consistent with findings from a large sample of MHT users (n = 5,164) from the UK Biobank that earlier MHT initiation is associated with less evident brain aging (calculated with measures of cortical thickness, cortical and subcortical volumes) among APOE4+ women only (de Lange et al., 2020).Furthermore, in a small sample (n = 25) of APOE4+ postmenopausal women in Beijing, China, women taking MHT for at least four years (n = 14) had greater hippocampal volumes than women who had never used MHT (n = 11;Yue et al., 2007).Here, we found that higher levels of endogenous E2 and E1 were associated with greater volume of the left caudal middle frontal gyrus, an area within the dlPFC.However, our findings generally indicate that endogenous estrogens in the postmenopause do not have a strong direct effect on regional brain volumes.Rather, our results suggest that the effect of endogenous estrogens on brain structure may depend on AD biomarker level and APOE4 carrier status, with higher endogenous estrogen levels being most advantageous for non-APOE4 carriers with lower levels of AD biomarkers.While the low levels of AD biomarkers captured in our sample do not meet the cut-offs to predict cognitive decline or dementia (Blennow et al., 2019;Brum et al., 2022), our findings indicate that biomarker levels within this range may affect brain structure when considering additional contributing factors such as estrogens and APOE genotype.
In our full sample analyses, we identified ten regions wherein the relationship between estrogens and volume depended on bloodbased AD biomarkers.The regions and patterns of associations were similar for E1 and E2 which suggests that the effects are not specific to a particular estrogen type.The ten regions with an interaction of estrogens and AD biomarkers were primarily located in the frontal lobe, several of which were within the ventral and dorsolateral PFC (e.g., pars orbitalis, pars triangularis, pars opercularis, caudal middle frontal gyrus).The PFC is a key region for executive function, working memory and attentional control (Fuster, 2001), and connectivity between the PFC and the hippocampus is crucial for episodic memory performance (Nyberg, 2016;Eichenbaum, 2017).Cognitive abilities mediated by the PFC, including working memory, encoding-related strategic processing, and executive functions, are maintained by estradiol, as evidenced by studies of oophorectomy among women (Phillips and Sherwin, 1992), pharmacological suppression of ovarian hormones via gonadotropin hormone agonists (Craig et al., 2008), and estrogen supplementation in non-human primates (Rapp et al., 2003).Thus, the findings here may have implications for women's performance in these cognitive domains.Although to our knowledge this is the first study to examine interactive associations of endogenous estrogens and amyloid with Interactive effects of estradiol and Aβ42/40 on regional brain volumes, stratified by APOE4 carrier status.Aβ42/40 is divided into quintiles.B, regression coefficient estimate for the interaction term; p, p value for the interaction term.10.3389/fnagi.2024.1426070 Frontiers in Aging Neuroscience 12 frontiersin.orgbrain volume, other examined interactions between biological sex and amyloid on brain volume and cognitive functions.For example, there is evidence of a sex difference in the association of Aβ-42 with cognitive function and brain volume, with females showing stronger associations of Aβ-42 with left hippocampal atrophy and with declining memory and executive function performance (Koran et al., 2017).Similar sex differences are observed in a triple transgenic animal model of AD, where females show higher Aβ accumulation in the frontal cortex and more severe cognitive deficits compared to males, an effect driven by prenatal exposure to estrogen in the females (Carroll et al., 2010).Circulating estrogens also appear to contribute to the sex difference in that transgenic mouse model, as depletion of sex steroid hormones via oophorectomy increased Aβ accumulation and decreased memory performance while administration of estradiol, but not progesterone, prevented these effects (Carroll et al., 2007).Together, these studies raise the possibility that endogenous estrogen may drive some of the sex differences in brain health.
Our findings demonstrate that postmenopausal women with the most severe AD biomarkers (i.e., low ratios of Aβ42/40 or Aβ42/p-tau 181) benefit more from higher levels of endogenous estrogens, compared to women with less severe AD biomarker ratios.That association, however, varied by APOE4 carrier status with benefit among non-APOE4 carriers but not among APOE4 carriers.These results were not driven by different levels of AD biomarkers between the two groups, as AD biomarkers did not differ by APOE4 carrier status in this group of postmenopausal women.Overall, these data suggest that regardless of AD biomarker levels, late midlife women who carry the APOE4 allele may be insensitive to the effects of high-normal levels of endogenous estrogen on cortical regions that support memory performance.Given prior work (Kantarci et al., 2016a;Saleh et al., 2023), it may be that higher levels of estrogen, such as those found in MHT, are needed to confer benefits in APOE4 carriers.
The study has notable strengths and limitations.This is the first study in late midlife women to examine whether the effects of estrogens and AD biomarkers on brain volumes differ by APOE4 carrier status.The study looked not only at E2 but also E1, the predominant estrogen in postmenopausal women.We had a Interactive effects of estradiol and Aβ42/p-tau 181 on regional brain volumes, stratified by APOE4 carrier status.Aβ42/p-tau 181 is divided into quintiles.B, regression coefficient estimate for the interaction term; p, p value for the interaction term.
well-characterized sample of midlife women and used highly sensitive estrogen assays.Even with a sample size of 171, we had limited power to test three-way interactive associations (i.e., estrogens by AD biomarkers by APOE4 carrier status).Our statistical approach therefore examined interactive associations of estrogens and AD biomarkers by APOE4 carrier status.We did not control for multiple comparisons but a priori limited our analyses to 21 ROIs in the temporal and prefrontal cortex, regions with higher densities of estrogen receptors.Some of the findings may be chance findings, and therefore future work is needed to determine if our findings replicate in other samples.

Conclusion
In conclusion, we demonstrate that late midlife postmenopausal women with the most severe AD biomarkers benefit most from greater endogenous estrogen levels.This finding is driven by APOE4 non-carriers, indicating that the direct and interactive effects of estrogens may not be beneficial for brain structure in APOE ε4 carriers regardless of AD biomarkers severity.These findings suggest that compared to non-carriers, APOE ε4+ women may be at increased risk of AD due to the relative insensitivity to potential benefits of endogenous estrogens on brain volumes in the postmenopause.Interactive effects of estrone and Aβ42/40 on regional brain volumes, stratified by APOE4 carrier status.Aβ42/40 is divided into quintiles.B, regression coefficient estimate for the interaction term; p, p value for the interaction term.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

FIGURE 7
FIGURE 7 Participants were enrolled in MsBrain, a cohort study of menopause and brain aging initiated in 2017 in Pittsburgh, PA,

TABLE 1
Regions of interest and their corresponding estrogen signaling.

TABLE 3
Main effects of APOE4 carrier status, E2, E1, and their interactive effects on regional brain volumes.

TABLE 4
Interactive effects of estrogens and biomarkers on regional brain volumes in the full sample.

TABLE 5
Interactive effects of estrogens and biomarkers on regional brain volumes, stratified by APOE4 genotype.
10.3389/fnagi.2024.1426070Frontiers in Aging Neuroscience 14 frontiersin.orgsubmitted work.HA reported receiving personal fees from Eisai outside the submitted work.PM reported receiving personal fees from Astellas Pharma, Bayer, Estrigenix, Alloy, and MidiHealth outside the submitted work.